Lymphatica Medtech

Lymphatica Medtech SA is a clinical-stage medical device company located in Ecublens, Switzerland. Founded in 2017 as a spin-off from the Angiology Division of Lausanne University Hospital and the Laboratory of Lymphatic and Cancer Bioengineering at the Swiss Federal Institute of Technology, the company focuses on improving the well-being of patients with lymphatic diseases, particularly chronic lymphedema. The company has developed LymphoDRAIN, the world’s first implantable system for treating chronic lymphedema. This innovative device features a subcutaneous implant that integrates a pumping technology, activated by a wearable device, to replace the lymphatic drainage function. Lymphatica Medtech aims to provide a new treatment option for the millions affected by chronic lymphedema, a condition that can lead to significant discomfort and disability. The company has secured substantial funding to support the clinical development of LymphoDRAIN and has received FDA Breakthrough Device Designation, underscoring the potential impact of its technology.

• Employees 13
• Founded 2017
• Total Funding $100165